Natco Pharma Ltd.
Nifty 500
Smallcap 50
Smallcap 100
Smallcap 250
₹816.50
-0.26%
Delayed · cached 15 min
Fair value analysis
NATCOPHARM
Natco Pharma Ltd.
₹818.65
Close used for this calculation
₹1,841.81Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
82/100
Quality radar
Consensus fair value
₹1,841.81
Below FV▲ +125.0% against the close used
Model range ₹860.54 – ₹3,566.83
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹860.54Fair value₹1,841.81Bull₹3,566.83
FairClose
52-week traded range
52W low ₹792.9552W high ₹1,206.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Natco Pharma Ltd. closed at ₹818.65, 55.6% below the consensus fair value of ₹1,841.81 drawn from 9 valuation models.
Financial DNA score 82/100 — Exceptional. P/E of 12.8x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹1,534.37
+87.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹860.54
+5.1%
√(22.5 × EPS × BVPS)
EPS=79.2, BVPS=415.56 · outside Graham range (P/E 12.8, P/B 2) — asset-light, treat as a rough floor
Graham Formula
₹3,566.83
+335.7%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹2,827.44
+245.4%
EPS × 35.7x (sector P/E)
EPS=79.2, Sector P/E=35.7x
Peter Lynch (PEG)
₹1,980.00
+141.9%
EPS × Growth% (PEG = 1 is fair)
EPS=79.2, g=25%
EV/EBITDA
₹1,644.03
+100.8%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=16.69B
Book Value (P/B)
₹1,153.17
+40.9%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=415.56, ROE=17.1%, g=6%, r=10%
Reverse DCF
₹818.65
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -1.9% | Historical: 25%
Margin of Safety
₹1,647.97
+101.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=2197.3, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.